Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

39.25
-0.8900-2.22%
Post-market: 39.250.00000.00%16:36 EDT
Volume:523.40K
Turnover:20.82M
Market Cap:2.28B
PE:-11.89
High:41.07
Open:39.97
Low:38.91
Close:40.14
Loading ...

Company Profile

Company Name:
Apogee Therapeutics
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
196
Office Location:
221 Crescent Street,Building 17,Suite 102b,Waltham,Massachusetts,United States
Zip Code:
02453
Fax:
- -
Introduction:
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Directors

Name
Position
Michael Henderson
Chief Executive Officer and Director
Peter Harwin
Chair and Director
Andrew Gottesdiener
Director
Jennifer Fox
Director
Nimish Shah
Director
Tomas Kiselak
Director
William Jones, Jr.
Director

Shareholders

Name
Position
Michael Henderson
Chief Executive Officer and Director
Jane Pritchett Henderson
Chief Financial Officer
Carl Dambkowski
Chief Medical Officer
Rebecca Dabora
Chief Technical Officer